Showing results (221-230 of 313) with videos related to

Sort By:
Pageof 32
Cancers|March 13, 2024
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 TrialScott R Solomon, Bayard L Powell, Jamie Koprivnikar, et al.
Cardio-Oncology (London, England)|November 26, 2025
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
Leukemia & Lymphoma|September 6, 2013
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapsePreetesh Jain, Hagop Kantarjian, Keyur Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancersHagop M Kantarjian, Varsha Gandhi, Peter Kozuch, et al.
American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Molecular Cancer Research : MCR|May 20, 2014
STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosisPing Li, David Harris, Zhiming Liu, et al.
Blood|December 13, 2006
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 studySteven M Kornblau, Deborah E Banker, Derek Stirewalt, et al.
Pageof 32